JP2010510223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510223A5 JP2010510223A5 JP2009537223A JP2009537223A JP2010510223A5 JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5 JP 2009537223 A JP2009537223 A JP 2009537223A JP 2009537223 A JP2009537223 A JP 2009537223A JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- tim
- antigen
- activity
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85939106P | 2006-11-15 | 2006-11-15 | |
| US92394507P | 2007-04-17 | 2007-04-17 | |
| PCT/US2007/024067 WO2008060617A2 (en) | 2006-11-15 | 2007-11-15 | Therapeutic uses of tim-3 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510223A JP2010510223A (ja) | 2010-04-02 |
| JP2010510223A5 true JP2010510223A5 (enExample) | 2012-01-26 |
Family
ID=39402274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537223A Withdrawn JP2010510223A (ja) | 2006-11-15 | 2007-11-15 | Ｔｉｍ−３調節物質の治療的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100061992A1 (enExample) |
| EP (1) | EP2081961A2 (enExample) |
| JP (1) | JP2010510223A (enExample) |
| AU (1) | AU2007319806A1 (enExample) |
| CA (1) | CA2668693A1 (enExample) |
| WO (1) | WO2008060617A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010084999A1 (en) * | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| CN103800906B (zh) * | 2009-03-25 | 2017-09-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
| AU2011262758B8 (en) * | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2014022332A1 (en) * | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| HK1213788A1 (zh) | 2012-10-12 | 2016-07-15 | 布里格姆及妇女医院股份有限公司 | 免疫應答的增强 |
| US20150297714A1 (en) | 2012-10-29 | 2015-10-22 | The Board Of Trustees Of The University Of Arkansas | Novel mucosal adjuvants and delivery systems |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CA2942245C (en) | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| SI3148579T1 (sl) | 2014-05-28 | 2021-07-30 | Agenus Inc. | Proti GITR antitelesa in postopki z njihovo uporabo |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| WO2016171722A1 (en) * | 2015-04-24 | 2016-10-27 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| WO2016179194A1 (en) * | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
| US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| MX394409B (es) * | 2016-03-04 | 2025-03-24 | Galectin Sciences Llc | Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos. |
| FR3051192B1 (fr) * | 2016-05-13 | 2020-12-25 | Univ De Lorraine | Methode de purification de proteines recombinantes par affinite basee sur l'activite lectinique du domaine crd d'une galectine |
| EP3464360B1 (en) | 2016-05-27 | 2025-11-12 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| KR102536302B1 (ko) * | 2020-02-25 | 2023-05-26 | 국립암센터 | Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| AU2022274001A1 (en) * | 2021-05-11 | 2023-12-21 | Griffith University | Immunogenic composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470428B2 (en) * | 2002-01-30 | 2008-12-30 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| CA2541006C (en) * | 2003-10-03 | 2015-02-17 | Brigham And Women's Hospital | Tim-3 polypeptides |
-
2007
- 2007-11-15 EP EP07867488A patent/EP2081961A2/en not_active Withdrawn
- 2007-11-15 CA CA002668693A patent/CA2668693A1/en not_active Abandoned
- 2007-11-15 WO PCT/US2007/024067 patent/WO2008060617A2/en not_active Ceased
- 2007-11-15 US US12/514,602 patent/US20100061992A1/en not_active Abandoned
- 2007-11-15 JP JP2009537223A patent/JP2010510223A/ja not_active Withdrawn
- 2007-11-15 AU AU2007319806A patent/AU2007319806A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510223A5 (enExample) | ||
| JP7215997B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 | |
| Foote et al. | A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice | |
| Avci et al. | Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference? AB Avci et al. | |
| Fury et al. | A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors | |
| US10392444B2 (en) | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer | |
| Xu et al. | Resident microglia activate before peripheral monocyte infiltration and p75NTR blockade reduces microglial activation and early brain injury after subarachnoid hemorrhage | |
| Xiao et al. | The IL-2/Anti-IL-2 complex attenuates cardiac ischaemia-reperfusion injury through expansion of regulatory T cells | |
| US20100310501A1 (en) | Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject | |
| Cook et al. | Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation | |
| EP1137766B1 (en) | Use of il-12 antibodies to treat psoriasis | |
| Weber et al. | Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma | |
| JP2004501631A5 (enExample) | ||
| AU2010248935B2 (en) | Methods and compositions for treating lupus | |
| JP2006523682A5 (enExample) | ||
| US20030007972A1 (en) | Cytokine antagonists and other biologics for the treatment of bone metastases | |
| JP2011507891A5 (enExample) | ||
| JP2002537362A (ja) | ビオチン化ケモカイン抗体複合体 | |
| De Benedetti et al. | In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist | |
| JP2021511296A (ja) | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 | |
| CA3118706A1 (en) | B-cell activating cd73 antibodies | |
| KR20200068746A (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) | |
| CN106459181A (zh) | α‑烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法 | |
| Shao | Biologic therapy in Sjögren’s syndrome | |
| Koschella et al. | CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells |